MD1432B2 - Metoda de tratament al starii dependente de estrogenii ovarieni - Google Patents

Metoda de tratament al starii dependente de estrogenii ovarieni

Info

Publication number
MD1432B2
MD1432B2 MD96-0323A MD960323A MD1432B2 MD 1432 B2 MD1432 B2 MD 1432B2 MD 960323 A MD960323 A MD 960323A MD 1432 B2 MD1432 B2 MD 1432B2
Authority
MD
Moldova
Prior art keywords
treatment
state depending
estrogens
quantity sufficient
ovarian estrogens
Prior art date
Application number
MD96-0323A
Other languages
English (en)
Other versions
MD1432C2 (ro
Inventor
Gary D Hodgen
Robert F Williams
Daniel Grow
Original Assignee
Hampton Roads Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hampton Roads Medical College filed Critical Hampton Roads Medical College
Publication of MD1432B2 publication Critical patent/MD1432B2/ro
Publication of MD1432C2 publication Critical patent/MD1432C2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
MD96-0323A 1994-02-04 1995-02-02 Metodă de tratament al stării dependente de estrogenii ovarieni MD1432C2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/191,631 US5681817A (en) 1994-02-04 1994-02-04 Treatment of ovarian estrogen dependent conditions
PCT/US1995/001479 WO1995020972A1 (en) 1994-02-04 1995-02-02 Treatment of ovarian estrogen dependent conditions

Publications (2)

Publication Number Publication Date
MD1432B2 true MD1432B2 (ro) 2000-03-31
MD1432C2 MD1432C2 (ro) 2000-09-30

Family

ID=22706258

Family Applications (1)

Application Number Title Priority Date Filing Date
MD96-0323A MD1432C2 (ro) 1994-02-04 1995-02-02 Metodă de tratament al stării dependente de estrogenii ovarieni

Country Status (29)

Country Link
US (1) US5681817A (ro)
EP (1) EP0785792B1 (ro)
JP (1) JP3130048B2 (ro)
KR (1) KR970700507A (ro)
CN (1) CN1144486A (ro)
AP (1) AP724A (ro)
AT (1) ATE179610T1 (ro)
AU (1) AU689229B2 (ro)
BG (1) BG62238B1 (ro)
BR (1) BR9506606A (ro)
CA (1) CA2182183C (ro)
CZ (1) CZ291709B6 (ro)
DE (1) DE69509544T2 (ro)
DK (1) DK0785792T3 (ro)
ES (1) ES2132645T3 (ro)
FI (1) FI963036L (ro)
GR (1) GR3030164T3 (ro)
HU (1) HUT74622A (ro)
LT (1) LT4182B (ro)
LV (1) LV11782B (ro)
MD (1) MD1432C2 (ro)
NZ (1) NZ281441A (ro)
OA (1) OA10777A (ro)
PL (1) PL178273B1 (ro)
RO (1) RO117420B1 (ro)
RU (1) RU2110274C1 (ro)
SK (1) SK96296A3 (ro)
TJ (1) TJ242B (ro)
WO (1) WO1995020972A1 (ro)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9700574A (es) * 1994-07-22 1997-12-31 Hampton Roads Medical College Metodo para establecer la secrecion de estrogeno tonico ovarico para regimenes terapeuticos prolongados.
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
AU9462498A (en) 1997-10-17 1999-05-10 Mochida Pharmaceutical Co., Ltd. Hysteromyoma remedy containing dienogest as the active ingredient
US6703367B1 (en) 1999-04-27 2004-03-09 Praecis Pharmaceuticals Inc. Methods for treating hot flashes and gynaecomastia
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6417214B1 (en) * 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US8193252B1 (en) 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
DE60036723T2 (de) * 1999-08-31 2008-07-17 Bayer Schering Pharma Aktiengesellschaft Mesoprogestine zur behandlung und vorbeugung von hormonabhängigen gutartigen gynekologischen störungen
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
CA2427731A1 (en) * 2000-10-30 2002-05-10 University Of Zurich Gnrh analogues for treatment of urinary incontinence
US7029657B2 (en) * 2002-08-02 2006-04-18 Balance Pharmaceuticals, Inc. Nasal spray steroid formulation and method
US6958142B2 (en) * 2002-08-02 2005-10-25 Balance Pharmaceuticals, Inc. Nasal spray formulation and method
US6960337B2 (en) * 2002-08-02 2005-11-01 Balance Pharmaceuticals, Inc. Methods and compositions for treating benign gynecological disorders
GB0302572D0 (en) 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
JP4992091B2 (ja) * 2005-02-17 2012-08-08 ハダシット メディカル リサーチ サービシーズ アンド デベロップメント リミテッド 子宮内膜症を治療するためのビスホスホネート
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
TWI455716B (zh) * 2006-10-24 2014-10-11 Repros Therapeutics Inc 選擇性黃體激素受體調節劑用於製造治療雌激素依賴性病症之藥物的用途
ES2643318T3 (es) 2006-10-24 2017-11-22 Repros Therapeutics Inc. Composiciones y métodos para suprimir la proliferación endometrial
WO2008144143A1 (en) * 2007-05-14 2008-11-27 Drugtech Corporation Endometriosis treatment
ES2467942T3 (es) * 2007-09-20 2014-06-13 Lapidot Medical Import And Marketing Ltd Composiciones y medios para tratar leiomiomas uterinos, leiomioma, mioma, fibroides uterinos, endometriosis, adenomiosis y trastornos relacionados por mifepristona.
RU2359684C1 (ru) * 2008-01-23 2009-06-27 Закрытое акционерное общество "СКАЙ ЛТД" Способ лечения эндометриоза
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
EP3560555A1 (en) 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
US4780461A (en) 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3347126A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE19975054I2 (de) 1987-08-08 2000-04-13 Akzo Nobel Nv Kontrazeptives Implantat
DE3744054A1 (de) 1987-12-21 1989-06-29 Schering Ag Verwendung von antigestagenen zur herstellung von arzneimitteln
DE3921059A1 (de) 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
DK0472725T3 (da) 1990-03-16 1997-11-03 Applied Research Systems Behandling af polycystisk ovariesygdom
US6827050B2 (en) 2001-12-21 2004-12-07 Caterpillar Inc Fluid control valve actuating system
US7283632B2 (en) 2003-09-09 2007-10-16 The Boeing Company Unauthorized access embedded software protection system

Also Published As

Publication number Publication date
WO1995020972A1 (en) 1995-08-10
ATE179610T1 (de) 1999-05-15
EP0785792A4 (ro) 1997-07-30
CA2182183C (en) 2003-09-16
AP9600840A0 (en) 1996-07-31
RU2110274C1 (ru) 1998-05-10
BR9506606A (pt) 1997-09-09
HUT74622A (en) 1997-01-28
TJ242B (en) 1999-11-24
OA10777A (en) 2002-12-23
CZ210396A3 (en) 1997-05-14
AU689229B2 (en) 1998-03-26
AU1838695A (en) 1995-08-21
MD1432C2 (ro) 2000-09-30
EP0785792A1 (en) 1997-07-30
ES2132645T3 (es) 1999-08-16
FI963036A0 (fi) 1996-08-01
FI963036A7 (fi) 1996-08-01
US5681817A (en) 1997-10-28
LV11782A (lv) 1997-06-20
DE69509544T2 (de) 1999-09-02
PL315792A1 (en) 1996-12-09
JPH09508418A (ja) 1997-08-26
PL178273B1 (pl) 2000-03-31
EP0785792B1 (en) 1999-05-06
NZ281441A (en) 1999-09-29
FI963036L (fi) 1996-08-01
LT96133A (en) 1997-01-27
AP724A (en) 1999-01-18
DE69509544D1 (de) 1999-06-10
LV11782B (en) 1997-12-20
BG62238B1 (bg) 1999-06-30
KR970700507A (ko) 1997-02-12
DK0785792T3 (da) 1999-10-18
LT4182B (en) 1997-06-25
CA2182183A1 (en) 1995-08-10
GR3030164T3 (en) 1999-08-31
CZ291709B6 (cs) 2003-05-14
SK96296A3 (en) 1997-07-09
JP3130048B2 (ja) 2001-01-31
BG100766A (bg) 1997-06-30
RO117420B1 (ro) 2002-03-29
HU9601969D0 (en) 1996-09-30
CN1144486A (zh) 1997-03-05

Similar Documents

Publication Publication Date Title
MD1432B2 (ro) Metoda de tratament al starii dependente de estrogenii ovarieni
Cohen et al. Direct injection of methylprednisolone sodium succinate in the treatment of solitary eosinophilic granuloma of bone: a report of 9 cases.
Stern et al. The use of the Leinbach prosthesis in intertrochanteric fractures of the hip
DE68928897D1 (de) Verfahren und system zur empfängnisverhütung
DK351887D0 (da) Kombinationsdosisform til hormonbehandling og kontraception for kvinder i praemenopausen
MY109309A (en) Improvements in or relating to somatostatins
RU93054017A (ru) Способ лечения остеопороза, композиция для лечения остеопороза, применение активно действующего на кости фосфоната и эстрогенного гормона для лечения остеопороза
Thoren et al. Preliminary study of the effects of growth hormone substitution therapy on bone mineral density and serum osteocalcin levels in adults with growth hormone deficiency
Lev-Ran Secondary amenorrhea resulting from uncontrolled weight-reducing diets
MY105798A (en) Treatment of leukocyte dysfunction with gm-csf.
Bolman III et al. Stimulation of gastrin secretion in the pig by parathyroid hormone and its inhibition by thyrocalcitonin
GR3032224T3 (en) Therapeutic agent for threatened abortion.
DE69227042D1 (de) Verfahren und zusammensetzungen zur verminderung von blutverlust
GB8727493D0 (en) Epidermal growth factor
Wagner et al. Effect of local or parenteral application of ACTH or hydrocortisone on bovine corpus luteum function
KR900017599A (ko) 종양 치료용 약학 조성물
Schneyer Calcitonin and the treatment of osteoporosis
Skouby et al. Clinical experience with the recently developed progestogens
Glasscock et al. Hormonal control of growth of the infant rat II. Effects of hypophysectomy, thyroidectomy and the combination of these operations: Evidence that neither TSH nor thyroxine is transferred via milk to suckling young
Niimura et al. Trochanteric Femoral Fractures treated with Compression Hip Screw
郑伯承 “PRIME MINISTER IN THE MOUNTAINS”—THE ANCIENT PHYSICIAN TAO HONGJING
Hassager et al. Epidemiology, biochemistry and some results with treatment of postmenopausal osteoporosis
de la Osa Gonzalez Clinical response of abnormal endometrial growth to hormonal treatment
Filer et al. Transdermal estrogen and prevention of osteoporosis.
Benmeir et al. Use of buried skin implants after recurrent failure of conventional skin grafting in a massive burn: the renewal of an old technique

Legal Events

Date Code Title Description
PD99 Pending application